Peroxisome Proliferator‐Activated Receptors in HBV‐Related Infection
Author(s) -
Laurent Dubuquoy,
Alexandre Louvet,
Antoine Hollebecque,
Philippe Mathurin,
Sébastien Dharancy
Publication year - 2009
Publication title -
ppar research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 49
eISSN - 1687-4765
pISSN - 1687-4757
DOI - 10.1155/2009/145124
Subject(s) - hepatocellular carcinoma , hepatitis b virus , peroxisome proliferator activated receptor , receptor , nuclear receptor , virology , medicine , virus , peroxisome , transcription factor , immunology , disease , bioinformatics , biology , cancer research , gene , genetics
Thirty years after its discovery, the hepatitis B virus (HBV) still remains a major global public health problem. Worldwide, two billion subjects have been infected, 350 million have a chronic infection and more than 600 000 die annually of HBV-related liver disease or hepatocellular carcinoma; new infections occur because of the presence of a large reservoir of chronic carriers of the virus. Since a decade several studies describe the interrelations between HBV and nuclear receptors and more particularly the peroxisome proliferator-activated receptors (PPARs). After a brief introduction, this review will make a rapid description of HBV incidence and biology. Then a report of the literature on the role of PPARs on viral transcription and replication will be developed. Finally, the role of HBV on PPAR γ expression and activity will be discussed. Concluding remarks and perspectives will close this review.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom